Futura Medical expects FDA approval for topical ED treatment during Q2
News release
by
Futura Medical PLC
London, UK
|
March 14, 2023 09:02 AM Eastern Daylight Time
Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Proactive's Thomas Warner after announcing the European online launch of topical erectile dysfunction (ED) treatment MED3000, under the brand name Eroxon.
Barder also gives an update on the company's discussions with the FDA regarding MED3000, saying that he expects approval to come during the second quarter.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
